U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry ABSOLUTE
Molecular Formula C21H28O2
Molecular Weight 312.4458
Optical Activity ( - )
Defined Stereocenters 6 / 6
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of LEVONORGESTREL

SMILES

CC[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C

InChI

InChIKey=WWYNJERNGUHSAO-XUDSTZEESA-N
InChI=1S/C21H28O2/c1-3-20-11-9-17-16-8-6-15(22)13-14(16)5-7-18(17)19(20)10-12-21(20,23)4-2/h2,13,16-19,23H,3,5-12H2,1H3/t16-,17+,18+,19-,20-,21-/m0/s1

HIDE SMILES / InChI

Molecular Formula C21H28O2
Molecular Weight 312.4458
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 6 / 6
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/25698840

Levonorgestrel (LNG) is a synthetic progestational hormone with actions similar to those of progesterone and about twice as potent as its racemic or (+-)-isomer (norgestrel). It is used for contraception, control of menstrual disorders, and treatment of endometriosis. It is usually supplied in a racemic mixture (Norgestrel, 6533-00-2). Only the levonorgestrel isomer is active. Within an Intrauterine device (IUD), sold as Mirena among others, it is effective for long term prevention of pregnancy. The local mechanism by which continuously released LNG enhances contraceptive effectiveness of Mirena has not been conclusively demonstrated. Studies of Mirena and similar LNG IUS prototypes have suggested several mechanisms that prevent pregnancy: thickening of cervical mucus preventing passage of sperm into the uterus, inhibition of sperm capacitation or survival, and alteration of the endometrium. Mirena has mainly local progestogenic effects in the uterine cavity. The high local levels of levonorgestrel lead to morphological changes including stromal pseudodecidualization, glandular atrophy, a leukocytic infiltration and a decrease in glandular and stromal mitoses. Ovulation is inhibited in some women using Mirena. In a 1-year study, approximately 45% of menstrual cycles were ovulatory, and in another study after 4 years, 75% of cycles were ovulatory. There has been much debate regarding levonorgestrel emergency contraception's (LNG-EC's) method of action since 1999 when the Food and Drug Administration first approved its use. Proponents of LNG-EC have argued that they have moral certitude that LNG-EC works via a non-abortifacient mechanism of action, and claim that all the major scientific and medical data consistently support this hypothesis. However, newer medical data serve to undermine the consistency of the non-abortifacient hypothesis and instead support the hypothesis that preovulatory administration of LNG-EC has significant potential to work via abortion. The implications of the newer data have important ramifications for medical personnel, patients, and both Catholic and non-Catholic emergency room protocols. In the future, technology such as the use of early pregnancy factor may have the potential to quantify how frequently preovulatory LNG-EC works via abortion. The latest scientific and medical evidence now demonstrates that levonorgestrel emergency contraception theoretically works via abortion quite often. The implications of the newer data have important ramifications for medical personnel, patients, and both Catholic and non-Catholic emergency room rape protocols.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Preventing
MIRENA

Approved Use

Mirena is indicated for intrauterine contraception for up to 5 years. Mirena is also indicated for the treatment of heavy menstrual bleeding in women who choose to use intrauterine contraception as their method of contraception. Mirena is recommended for women who have had at least one child. The system should be replaced after 5 years if continued use is desired.

Launch Date

2000
Primary
MIRENA

Approved Use

Mirena is indicated for intrauterine contraception for up to 5 years. Mirena is also indicated for the treatment of heavy menstrual bleeding in women who choose to use intrauterine contraception as their method of contraception. Mirena is recommended for women who have had at least one child. The system should be replaced after 5 years if continued use is desired.

Launch Date

2000
Preventing
OVRETTE

Approved Use

Progestin-only oral contraceptives are indicated for the prevention of pregnancy.

Launch Date

1973
Preventing
ELINEST

Approved Use

Oral contraceptives are indicated for the prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception.

Launch Date

2012
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
14.11 ng/mL
0.75 mg single, oral
dose: 0.75 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
LEVONORGESTREL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: FASTED
16.2 ng/mL
1.5 mg single, oral
dose: 1.5 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
LEVONORGESTREL blood
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
123.1 ng × h/mL
0.75 mg single, oral
dose: 0.75 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
LEVONORGESTREL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: FASTED
360.1 ng × h/mL
1.5 mg single, oral
dose: 1.5 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
LEVONORGESTREL blood
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
24.4 h
0.75 mg single, oral
dose: 0.75 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
LEVONORGESTREL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: FASTED
29.7 h
1.5 mg single, oral
dose: 1.5 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
LEVONORGESTREL blood
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: FASTED
Doses

Doses

DosePopulationAdverse events​
20 ug 1 times / day multiple, intrauterine
Recommended
Dose: 20 ug, 1 times / day
Route: intrauterine
Route: multiple
Dose: 20 ug, 1 times / day
Sources:
healthy, 16-45
Health Status: healthy
Age Group: 16-45
Sex: F
Sources:
Disc. AE: Bleeding...
AEs leading to
discontinuation/dose reduction:
Bleeding (1.5%)
Sources:
20 ug 1 times / day multiple, intrauterine
Recommended
Dose: 20 ug, 1 times / day
Route: intrauterine
Route: multiple
Dose: 20 ug, 1 times / day
Sources:
healthy, 27.3 ± 5.7
Health Status: healthy
Age Group: 27.3 ± 5.7
Sex: F
Sources:
Disc. AE: Menstrual irregularity, Amenorrhea...
AEs leading to
discontinuation/dose reduction:
Menstrual irregularity (0.7%)
Amenorrhea (0.06%)
Sources:
90 ug 1 times / day multiple, oral
Recommended
Dose: 90 ug, 1 times / day
Route: oral
Route: multiple
Dose: 90 ug, 1 times / day
Sources:
healthy, 27.6±6.7
Health Status: healthy
Age Group: 27.6±6.7
Sex: F
Sources:
Disc. AE: Metrorrhagia, Bleeding vaginal...
AEs leading to
discontinuation/dose reduction:
Metrorrhagia (8.7%)
Bleeding vaginal (3.7%)
Sources:
AEs

AEs

AESignificanceDosePopulation
Bleeding 1.5%
Disc. AE
20 ug 1 times / day multiple, intrauterine
Recommended
Dose: 20 ug, 1 times / day
Route: intrauterine
Route: multiple
Dose: 20 ug, 1 times / day
Sources:
healthy, 16-45
Health Status: healthy
Age Group: 16-45
Sex: F
Sources:
Amenorrhea 0.06%
Disc. AE
20 ug 1 times / day multiple, intrauterine
Recommended
Dose: 20 ug, 1 times / day
Route: intrauterine
Route: multiple
Dose: 20 ug, 1 times / day
Sources:
healthy, 27.3 ± 5.7
Health Status: healthy
Age Group: 27.3 ± 5.7
Sex: F
Sources:
Menstrual irregularity 0.7%
Disc. AE
20 ug 1 times / day multiple, intrauterine
Recommended
Dose: 20 ug, 1 times / day
Route: intrauterine
Route: multiple
Dose: 20 ug, 1 times / day
Sources:
healthy, 27.3 ± 5.7
Health Status: healthy
Age Group: 27.3 ± 5.7
Sex: F
Sources:
Bleeding vaginal 3.7%
Disc. AE
90 ug 1 times / day multiple, oral
Recommended
Dose: 90 ug, 1 times / day
Route: oral
Route: multiple
Dose: 90 ug, 1 times / day
Sources:
healthy, 27.6±6.7
Health Status: healthy
Age Group: 27.6±6.7
Sex: F
Sources:
Metrorrhagia 8.7%
Disc. AE
90 ug 1 times / day multiple, oral
Recommended
Dose: 90 ug, 1 times / day
Route: oral
Route: multiple
Dose: 90 ug, 1 times / day
Sources:
healthy, 27.6±6.7
Health Status: healthy
Age Group: 27.6±6.7
Sex: F
Sources:
OverviewDrug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
likely
no [IC50 >133 uM]
no [IC50 >133 uM]
no [IC50 >133 uM]
no [IC50 >133 uM]
no [IC50 >250 uM]
no [IC50 >250 uM]
no [IC50 >250 uM]
no [IC50 >250 uM]
no [IC50 >250 uM]
no [IC50 >250 uM]
yes [IC50 13.6 uM]
yes
yes
Drug as victim
PubMed

PubMed

TitleDatePubMed
Post-marketing surveillance of Norplant contraceptive implants: I. Contraceptive efficacy and reproductive health.
2001 Apr
Rat uterine complement C3 expression as a model for progesterone receptor modulators: characterization of the new progestin trimegestone.
2001 Aug
Combined oral hormone replacement therapy formulations.
2001 Aug
Preclinical profiles of progestins used in formulations of oral contraceptives and hormone replacement therapy.
2001 Aug
What is the risk of venous thromboembolism (VTE) among women taking third-generation oral contraceptives (OCs) in comparison with those taking contraceptives containing levonorgestrel?
2001 Feb
Contraceptive use at the family planning clinic of the University of Nigeria Teaching Hospital, Enugu, Nigeria.
2001 Jan
Sixty thousand woman-years of experience on the levonorgestrel intrauterine system: an epidemiological survey in Finland.
2001 Jan
Effects of oral contraceptives on breast epithelial proliferation.
2001 Jan
Comparison of the lipoprotein, carbohydrate, and hemostatic effects of phasic oral contraceptives containing desogestrel or levonorgestrel.
2001 Jan
Quality of life and cost-effectiveness of levonorgestrel-releasing intrauterine system versus hysterectomy for treatment of menorrhagia: a randomised trial.
2001 Jan 27
Effects of two low-dose oral contraceptives containing ethinylestradiol and either desogestrel or levonorgestrel on serum lipids and lipoproteins with particular regard to LDL size.
2001 Jul
Norgestimate. From the laboratory to three clinical indications.
2001 Jul
A village would be nice but...it takes a long-acting contraceptive to prevent repeat adolescent pregnancies.
2001 Jul
The development and regression of deciduosarcomas and other lesions caused by estrogens and progestins in rabbits.
2001 Jul-Aug
Weight change and adverse event incidence with a low-dose oral contraceptive: two randomized, placebo-controlled trials.
2001 Jun
Comparison of a novel norgestimate/ethinyl estradiol oral contraceptive (Ortho Tri-Cyclen Lo) with the oral contraceptive Loestrin Fe 1/20.
2001 Jun
Treatment of menorrhagia with a novel 'frameless' intrauterine levonorgestrel-releasing drug delivery system: a pilot study.
2001 Jun
Co-localization of matrix metalloproteinase-1 and mast cell tryptase in the human uterus.
2001 Jun
Treatment of menorrhagia.
2001 Jun 9
Postmarketing surveillance study of Norplant in developing countries.
2001 Jun 9
Clinical recommendations for oxcarbazepine.
2001 Mar
Implanon contraceptive implants: effects on carbohydrate metabolism.
2001 Mar
The effects of peri-ovulatory administration of levonorgestrel on the menstrual cycle.
2001 Mar
Preferential prescribing of type of combined oral contraceptive pill by general practitioners to teenagers with acne.
2001 Mar
New IUD approved.
2001 Mar
Use of a levonorgestrel-releasing intrauterine device in the treatment of rectovaginal endometriosis.
2001 Mar
Contraception in the adolescent: an update.
2001 Mar
Constant estrogen, intermittent progestogen vs. continuous combined hormone replacement therapy: tolerability and effect on vasomotor symptoms.
2001 Mar
Norplant and other implantable contraceptives.
2001 Mar
Levonorgestrel-releasing intrauterine devices.
2001 Mar 10
[Low-dose oral contraception and bone density].
2001 Sep
Levonorgestrel-releasing IUD and breast cancer.
2001 Sep
Determination of circular dichroism and ultraviolet spectral parameters of norgestimate- and other Delta(4)-3-ketosteroid oxime isomers via normal phase HPLC method.
2001 Sep
Contraceptive dispensing and selection in school-based health centers.
2001 Sep
Patents

Sample Use Guides

In Vivo Use Guide
OVRETTE tablets (0.075 mg norgestrel) are available in packages of 6 PILPAK dispensers with 28 tablets each as follows: NDC 0008-0062-01, yellow, round tablet marked "WYETH" on one side and "62" on reverse side. To achieve maximum contraceptive effectiveness, OVRETTE must be taken exactly as directed. One tablet is taken every day, at the same time. Administration is continuous, with no interruption between pill packs.
Route of Administration: Oral
In Vitro Use Guide
Norgestrel stimulated MCF-7 cell proliferation at a concentration of 10(-8) M.
Substance Class Chemical
Created
by admin
on Mon Mar 31 17:54:06 GMT 2025
Edited
by admin
on Mon Mar 31 17:54:06 GMT 2025
Record UNII
5W7SIA7YZW
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
LEVONORGESTREL
EP   HSDB   INN   JAN   MART.   ORANGE BOOK   USAN   USP   USP-RS   VANDF   WHO-DD   WHO-IP  
INN   USAN  
Official Name English
ALESSE COMPONENT LEVONORGESTREL
Preferred Name English
LEVONORGESTREL [USP IMPURITY]
Common Name English
KURVELO COMPONENT LEVONORGESTREL
Brand Name English
AVIANE COMPONENT LEVONORGESTREL
Brand Name English
TRIPHASIL COMPONENT LEVONORGESTREL
Brand Name English
NSC-744007
Code English
LEVONORGESTREL [MART.]
Common Name English
levonorgestrel [INN]
Common Name English
NORGESTREL (-)-FORM [MI]
Common Name English
LEVONORGESTREL [EP MONOGRAPH]
Common Name English
LESSINA COMPONENT LEVONORGESTREL
Brand Name English
NORDETTE COMPONENT LEVONORGESTREL
Brand Name English
CLIMARA PRO COMPONENT LEVONORGESTREL
Common Name English
LOSEASONIQUE COMPONENT LEVONORGESTREL
Common Name English
ELIFEMME COMPONENT LEVONORGESTREL
Brand Name English
LNG
Common Name English
NORGESTIMATE IMPURITY B [EP IMPURITY]
Common Name English
Levonorgestrel [WHO-DD]
Common Name English
PREVEN COMPONENT LEVONORGESTREL
Common Name English
SEASONIQUE COMPONENT LEVONORGESTREL
Common Name English
LEVONORGESTREL [JAN]
Common Name English
MARLISSA COMPONENT LEVONORGESTREL
Brand Name English
LILETTA
Brand Name English
LEVONORGESTREL [USP-RS]
Common Name English
NORGESTREL (-)-FORM
MI  
Common Name English
WY-5104
Code English
LEVLITE COMPONENT LEVONORGESTREL
Common Name English
LEVONORGESTREL [ORANGE BOOK]
Common Name English
MYZILRA COMPONENT LEVONORGESTREL
Brand Name English
(-)-13-ETHYL-17-HYDROXY-18,19-DINOR-17.ALPHA.-PREGN-4-EN-20-YN-3-ONE
Common Name English
KYLEENA COMPONENT LEVONORGESTREL
Brand Name English
TRIVORA COMPONENT LEVONORGESTREL
Brand Name English
BAY86-5028
Code English
ALTAVERA COMPONENT LEVONORGESTREL
Common Name English
LYBREL COMPONENT LEVONORGESTREL
Common Name English
VIENVA COMPONENT LEVONORGESTREL
Brand Name English
PLASTIC IUD WITH LEVONORGESTREL
Common Name English
LEVONORGESTREL [WHO-IP]
Common Name English
ENPRESSE COMPONENT LEVONORGESTREL
Brand Name English
SETLAKIN COMPONENT LEVONORGESTREL
Brand Name English
SEASONALE COMPONENT LEVONORGESTREL
Common Name English
LEVONORGESTRELUM [WHO-IP LATIN]
Common Name English
MIRENA
Brand Name English
LEVONORGESTREL [USAN]
Common Name English
LEVONORGESTREL [USP MONOGRAPH]
Common Name English
TWIRLA COMPONENT LEVONORGESTREL
Brand Name English
INTROVALE COMPONENT LEVONORGESTREL
Common Name English
QUASENSE COMPONENT LEVONORGESTREL
Common Name English
NORPLANT
Brand Name English
LEVORA COMPONENT LEVONORGESTREL
Brand Name English
18,19-DINORPREGN-4-EN-20-YN-3-ONE, 13-ETHYL-17-HYDROXY-, (17.ALPHA.)-(-)-
Common Name English
OPCICON ONE-STEP COMPONENT LEVONORGESTREL
Brand Name English
AFIRMELLE COMPONENT LEVONORGESTREL
Brand Name English
QUARTETTE COMPONENT LEVONORGESTREL
Brand Name English
FALLBACK SOLO
Brand Name English
NORGESTREL, (-)-
Common Name English
ORSYTHIA COMPONENT LEVONORGESTREL
Brand Name English
PORTIA COMPONENT LEVONORGESTREL
Brand Name English
PLAN B
Brand Name English
IMPLANT WITH LEVONORGESTREL
Common Name English
LEVONORGESTREL [HSDB]
Common Name English
LEVONORGESTREL [VANDF]
Common Name English
LEVONEST COMPONENT LEVONORGESTREL
Common Name English
Classification Tree Code System Code
WHO-ATC G03AC03
Created by admin on Mon Mar 31 17:54:06 GMT 2025 , Edited by admin on Mon Mar 31 17:54:06 GMT 2025
WHO-VATC QG03AC03
Created by admin on Mon Mar 31 17:54:06 GMT 2025 , Edited by admin on Mon Mar 31 17:54:06 GMT 2025
NDF-RT N0000011301
Created by admin on Mon Mar 31 17:54:06 GMT 2025 , Edited by admin on Mon Mar 31 17:54:06 GMT 2025
WHO-VATC QG03AA07
Created by admin on Mon Mar 31 17:54:06 GMT 2025 , Edited by admin on Mon Mar 31 17:54:06 GMT 2025
WHO-ESSENTIAL MEDICINES LIST 18.3.1 (ETH/LEV)
Created by admin on Mon Mar 31 17:54:06 GMT 2025 , Edited by admin on Mon Mar 31 17:54:06 GMT 2025
WHO-VATC QG03AB03
Created by admin on Mon Mar 31 17:54:06 GMT 2025 , Edited by admin on Mon Mar 31 17:54:06 GMT 2025
WHO-ATC G03AA07
Created by admin on Mon Mar 31 17:54:06 GMT 2025 , Edited by admin on Mon Mar 31 17:54:06 GMT 2025
WHO-ATC G03AD01
Created by admin on Mon Mar 31 17:54:06 GMT 2025 , Edited by admin on Mon Mar 31 17:54:06 GMT 2025
WHO-ATC G03FB09
Created by admin on Mon Mar 31 17:54:06 GMT 2025 , Edited by admin on Mon Mar 31 17:54:06 GMT 2025
NCI_THESAURUS C776
Created by admin on Mon Mar 31 17:54:06 GMT 2025 , Edited by admin on Mon Mar 31 17:54:06 GMT 2025
NDF-RT N0000175830
Created by admin on Mon Mar 31 17:54:06 GMT 2025 , Edited by admin on Mon Mar 31 17:54:06 GMT 2025
LIVERTOX 555
Created by admin on Mon Mar 31 17:54:06 GMT 2025 , Edited by admin on Mon Mar 31 17:54:06 GMT 2025
WHO-ATC G03FA11
Created by admin on Mon Mar 31 17:54:06 GMT 2025 , Edited by admin on Mon Mar 31 17:54:06 GMT 2025
NDF-RT N0000175602
Created by admin on Mon Mar 31 17:54:06 GMT 2025 , Edited by admin on Mon Mar 31 17:54:06 GMT 2025
NDF-RT N0000175832
Created by admin on Mon Mar 31 17:54:06 GMT 2025 , Edited by admin on Mon Mar 31 17:54:06 GMT 2025
WHO-VATC QG03AD01
Created by admin on Mon Mar 31 17:54:06 GMT 2025 , Edited by admin on Mon Mar 31 17:54:06 GMT 2025
WHO-VATC QG03FB09
Created by admin on Mon Mar 31 17:54:06 GMT 2025 , Edited by admin on Mon Mar 31 17:54:06 GMT 2025
WHO-VATC QG03FA11
Created by admin on Mon Mar 31 17:54:06 GMT 2025 , Edited by admin on Mon Mar 31 17:54:06 GMT 2025
WHO-ESSENTIAL MEDICINES LIST 18.3.1
Created by admin on Mon Mar 31 17:54:06 GMT 2025 , Edited by admin on Mon Mar 31 17:54:06 GMT 2025
WHO-ATC G03AB03
Created by admin on Mon Mar 31 17:54:06 GMT 2025 , Edited by admin on Mon Mar 31 17:54:06 GMT 2025
Code System Code Type Description
EPA CompTox
DTXSID3036496
Created by admin on Mon Mar 31 17:54:06 GMT 2025 , Edited by admin on Mon Mar 31 17:54:06 GMT 2025
PRIMARY
RS_ITEM_NUM
1362602
Created by admin on Mon Mar 31 17:54:06 GMT 2025 , Edited by admin on Mon Mar 31 17:54:06 GMT 2025
PRIMARY
DAILYMED
5W7SIA7YZW
Created by admin on Mon Mar 31 17:54:06 GMT 2025 , Edited by admin on Mon Mar 31 17:54:06 GMT 2025
PRIMARY
LACTMED
Intrauterine Levonorgestrel
Created by admin on Mon Mar 31 17:54:06 GMT 2025 , Edited by admin on Mon Mar 31 17:54:06 GMT 2025
PRIMARY
INN
3475
Created by admin on Mon Mar 31 17:54:06 GMT 2025 , Edited by admin on Mon Mar 31 17:54:06 GMT 2025
PRIMARY
EVMPD
SUB08483MIG
Created by admin on Mon Mar 31 17:54:06 GMT 2025 , Edited by admin on Mon Mar 31 17:54:06 GMT 2025
PRIMARY
PUBCHEM
13109
Created by admin on Mon Mar 31 17:54:06 GMT 2025 , Edited by admin on Mon Mar 31 17:54:06 GMT 2025
PRIMARY
MESH
D016912
Created by admin on Mon Mar 31 17:54:06 GMT 2025 , Edited by admin on Mon Mar 31 17:54:06 GMT 2025
PRIMARY
ECHA (EC/EINECS)
212-349-8
Created by admin on Mon Mar 31 17:54:06 GMT 2025 , Edited by admin on Mon Mar 31 17:54:06 GMT 2025
PRIMARY
NSC
744007
Created by admin on Mon Mar 31 17:54:06 GMT 2025 , Edited by admin on Mon Mar 31 17:54:06 GMT 2025
PRIMARY
LACTMED
Oral Levonorgestrel
Created by admin on Mon Mar 31 17:54:06 GMT 2025 , Edited by admin on Mon Mar 31 17:54:06 GMT 2025
PRIMARY
MERCK INDEX
m8063
Created by admin on Mon Mar 31 17:54:06 GMT 2025 , Edited by admin on Mon Mar 31 17:54:06 GMT 2025
PRIMARY Merck Index
WHO INTERNATIONAL PHARMACOPEIA
LEVONORGESTREL
Created by admin on Mon Mar 31 17:54:06 GMT 2025 , Edited by admin on Mon Mar 31 17:54:06 GMT 2025
PRIMARY Description: A white or almost white, crystalline powder; odourless. Solubility: Practically insoluble in water; slightly soluble in ethanol (~750 g/l) TS and ether R. Category: Contraceptive. Storage: Levonorgestrel should be kept in a well-closed container, protected from light.Definition: Levonorgestrel contains not less than 98.0% and not more than 102.0% of C21H28O2, calculated with reference to the dried substance.
ChEMBL
CHEMBL1389
Created by admin on Mon Mar 31 17:54:06 GMT 2025 , Edited by admin on Mon Mar 31 17:54:06 GMT 2025
PRIMARY
LACTMED
Levonorgestrel Implant
Created by admin on Mon Mar 31 17:54:06 GMT 2025 , Edited by admin on Mon Mar 31 17:54:06 GMT 2025
PRIMARY
FDA UNII
5W7SIA7YZW
Created by admin on Mon Mar 31 17:54:06 GMT 2025 , Edited by admin on Mon Mar 31 17:54:06 GMT 2025
PRIMARY
DRUG CENTRAL
1572
Created by admin on Mon Mar 31 17:54:06 GMT 2025 , Edited by admin on Mon Mar 31 17:54:06 GMT 2025
PRIMARY
DRUG BANK
DB00367
Created by admin on Mon Mar 31 17:54:06 GMT 2025 , Edited by admin on Mon Mar 31 17:54:06 GMT 2025
PRIMARY
CHEBI
6443
Created by admin on Mon Mar 31 17:54:06 GMT 2025 , Edited by admin on Mon Mar 31 17:54:06 GMT 2025
PRIMARY
SMS_ID
100000091059
Created by admin on Mon Mar 31 17:54:06 GMT 2025 , Edited by admin on Mon Mar 31 17:54:06 GMT 2025
PRIMARY
CAS
797-63-7
Created by admin on Mon Mar 31 17:54:06 GMT 2025 , Edited by admin on Mon Mar 31 17:54:06 GMT 2025
PRIMARY
HSDB
6483
Created by admin on Mon Mar 31 17:54:06 GMT 2025 , Edited by admin on Mon Mar 31 17:54:06 GMT 2025
PRIMARY
RXCUI
6373
Created by admin on Mon Mar 31 17:54:06 GMT 2025 , Edited by admin on Mon Mar 31 17:54:06 GMT 2025
PRIMARY RxNorm
IUPHAR
2881
Created by admin on Mon Mar 31 17:54:06 GMT 2025 , Edited by admin on Mon Mar 31 17:54:06 GMT 2025
PRIMARY
WIKIPEDIA
LEVONORGESTREL
Created by admin on Mon Mar 31 17:54:06 GMT 2025 , Edited by admin on Mon Mar 31 17:54:06 GMT 2025
PRIMARY
NCI_THESAURUS
C47585
Created by admin on Mon Mar 31 17:54:06 GMT 2025 , Edited by admin on Mon Mar 31 17:54:06 GMT 2025
PRIMARY
Related Record Type Details
ENANTIOMER -> ENANTIOMER
RACEMATE -> ENANTIOMER
Related Record Type Details
METABOLITE ACTIVE -> PARENT
METABOLITE INACTIVE -> PARENT
PLASMA; URINE
PARENT -> METABOLITE ACTIVE
Related Record Type Details
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
PARENT -> IMPURITY
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
impurity O at 200 nm: maximum 0.3 per cent
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Related Record Type Details
ACTIVE MOIETY